Rheumatoid arthritis is a chronic inflamatory disorder which involves the immobilicity of the joint clinical course of the disease is very wide ranging from mild to server disease with extra articular manifestation NSAIDS, disease modifying and rheumatic drugs (DMARD) like methotrexate, sulfasalazine, Hydroxychloroquire are used for treatment. When used as a single drug therapy the efficacy and potenty of these drugs are low therefore multidrug therapy is used more than morodrug therapy. Methortrexate is the primary drug of Rleamatoid arthritis. Suggested mechanism includes (I) inhibition of T- cell proliferation by affecting purine and pyrimidine metabolism (II) inhibits aceumulation of monocytes at the site of inflammation in the joints. Pioglitazone is oral antidiafetic drugs. They induce apoptosis in the mecrophage and T-cymptocytes which are lmportant in perpituatiing rhenrnatoid arthritis. Prerent study was done to find out the effent of methotrexate and pioglitanone combination thesapy in the treatment of rheumatoid arthritis in albino rat models.
Methods: Arthritis was induced in twenty (20) albino rats by giving single dose of subcutaneous injeetion into five groups. Each group contain four rats two control groups one group treated with methotrexate only, one group with pioglitazone only, one with combined methotrexate anp pioglitazone. Treatment was given from day 10 to day 21 of the induction of diseace. Parameters used for the assessment were paw edema & Rediological assessment of joint. P value of 0.05 was considered significant. Paw diameter on day zero paw diameter of both hind limbs of each rat was measured. These measurements were repeated on day 3, 6, 9, 12, 15, 18 and 21 after enjection of CFA. Pas diameter in group II to V on day I increases upto 0.71 ± 0.013, 0.72 ± 0.013, 0.73 ± 0.014, 0.7 ± 0.014 as compared to group I (0.62 ± 0.022). However after treatment paw diameter on day 21 decreared from the value of day 9 in group III to V (0.68±0.012, 0.66±0.2, 0.63±0.011) but in group II value increases upto 0.78±0.019 value in the group I was constant.
Conclusion: Significant improvement was observed in the group treated with methotrexate and combination of methotrexate and pioglitazone as compared to piogitazone mono drug therapy which shous no significant improment. We concluded that methotrexate and pioglitanove combination offer better control in rheumatoid arthritis as compared to mono therapy with methopexate or pioglitazone.